登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由南京鼓楼医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07314372,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed hepatocellular carcinoma (HCC).
入选标准第 2 条
Child-Pugh class A or B (≤7 points).
入选标准第 8 条
ECOG performance status 0-1.
入选标准第 9 条
ANC ≥1.5 × 10⁹/L
入选标准第 11 条
Platelets ≥75 × 10⁹/L
入选标准第 12 条
Hemoglobin ≥90 g/L
入选标准第 13 条
Total bilirubin ≤1.5 × ULN
入选标准第 15 条
ALT and AST ≤3 × ULN
入选标准第 16 条
Serum creatinine ≤1.5 × ULN or creatinine clearance >50 mL/min
入选标准第 17 条
INR ≤1.2 or PT within 2 seconds above ULN
入选标准第 18 条
At least one measurable lesion according to RECIST v1.1.
入选标准第 6 条
Known HIV infection or other causes of immunodeficiency.
排除标准第 16 条
Women of childbearing potential must have a negative pregnancy test; participants of reproductive potential must agree to effective contraception during treatment and for 6 months afterward.
入选标准第 22 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07314372,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Adults ≥18 years of age who voluntarily agree to participate and sign informed consent. Histologically or cytologically confirmed hepatocellular carcinoma (HCC). Unresectable or not suitable for curative local therapy, or progression after prior surgery or local therapy. BCLC stage B or C. No prior systemic therapy for HCC. At least one measurable lesion according to RECIST v1.1. Availability of fresh or archival tumor tissue for FAD subtype testing; if not available at screening, MRI fat fraction may be used temporarily. Child-Pugh class A or B (≤7 points). ECOG performance status 0-1. Adequate organ function, including: ANC ≥1.5 × 10⁹/L Platelets ≥75 × 10⁹/L Hemoglobin ≥90 g/L Albumin ≥30 g/L Total bilirubin ≤1.5 × ULN ALT and AST ≤3 × ULN Serum creatinine ≤1.5 × ULN or creatinine clearance >50 mL/min INR ≤1.2 or PT within 2 seconds above ULN Urine protein <2+ or 24-hour urine protein <1.0 g Controlled HBV infection (HBV-DNA <2000 IU/mL; if above this level, ≥1 week of antiviral therapy with ≥1-log reduction prior to first dose). HCV-positive individuals must be managed per clinical guidelines. Life expectancy ≥12 weeks. Women of childbearing potential must have a negative pregnancy test; participants of reproductive potential must agree to effective contraception during treatment and for 6 months afterward.排除标准:Exclusion Criteria:
Non-HCC primary liver cancers (e.g., cholangiocarcinoma, combined HCC-CCA). F3 subtype without liver lesions on imaging. Clinically significant ascites requiring therapeutic intervention, or uncontrolled pleural/pericardial effusion. Interstitial lung disease, pneumonitis requiring steroids, or active pulmonary infection. Active or history of autoimmune disease requiring systemic treatment (exceptions allowed per protocol, e.g., controlled hypothyroidism). Recent use (within 2 weeks) of systemic immunosuppressive therapy >10 mg/day prednisone equivalent. Gastrointestinal bleeding within 6 months, high-risk varices, active ulcers, fistula, perforation, or intra-abdominal abscess. Known bleeding or clotting disorders; therapeutic anticoagulation not permitted. Thromboembolic events within 6 months (e.g., stroke, PE). Significant cardiovascular disease, including NYHA class ≥II heart failure, recent MI (within 1 year), unstable angina, clinically significant arrhythmias, or QTc prolongation. Uncontrolled hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg despite treatment), or history of hypertensive crisis. Major vascular disease within 6 months (e.g., arterial thrombosis, aneurysm requiring repair). Serious non-healing wounds, active ulcers, or fractures. Inability to swallow oral medication or conditions affecting drug absorption. Severe infection within 4 weeks, therapeutic antibiotics within 14 days, fever ≥38.5°C within 7 days before enrollment, or WBC >15 × 10⁹/L. Known HIV infection or other causes of immunodeficiency. Receipt of live attenuated vaccines within 28 days before treatment. Any condition that, in the investigator's judgment, would interfere with study participation or interpretation of results, including substance abuse, severe psychiatric illness, or social factors.
引自 ClinicalTrials.gov, NCT07314372, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07314372,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。